1-7 of 7
Ross La Motte-Mohs
Close
Sort by
Journal Articles

Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

Danny V Jeyaraju, Sheida Hayati, Ann Polonskaia, Maryam Alapa, Manuel Ugidos, Andrew Browne, Alberto Risueño, Patrick Hagner, Vikas Gupta, Moshe Talpaz, Christopher Hernandez, Vincent Chia, Patricia Martin-Regueira, Daniel Lopes de Menezes, Ross La Motte-Mohs, Rajasekhar NVS Suragani, Anita K. Gandhi
Journal: Blood
Blood (2022) 140 (Supplement 1): 3865–3867.
https://doi.org/10.1182/blood-2022-166407
Published: 2022
Journal Articles

Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)

Danny V Jeyaraju, Maryam Alapa, Aimee O'Donohue, Ross La Motte-Mohs, Isaac W. Boss, Patrick Hagner, Michael Pourdehnad, Michael R. Burgess, William E. Pierceall, Anjan Thakurta
Journal: Blood
Blood (2022) 140 (Supplement 1): 7070–7071.
https://doi.org/10.1182/blood-2022-157927
Published: 2022
Journal Articles

Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart ® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Sergio Rutella, MD PhD FRCPath, Sarah E. Church, PhD, Jayakumar Vadakekolathu, PhD, Elena Viboch, MSc, Amy H Sullivan, BSc, Tressa Hood, MSc, Sarah E. Warren, PhD, Alessandra Cesano, MD PhD, Ross La Motte-Mohs, PhD, John Muth, MS, Helene Lelièvre, PhD PharmD, Bob Lowenberg, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 444.
https://doi.org/10.1182/blood-2018-99-111539
Published: 2018
Journal Articles

A Next-Generation Fc-Bearing CD3-Engaging Bispecific DART ® Platform with Extended Pharmacokinetic and Expanded Pharmacologic Window: Characterization As CD123 x CD3 and CD19 x CD3 DART Molecules

Ezio Bonvini, MD, Ross La Motte-Mohs, PhD, Ling Huang, Chia-Ying Kao Lam, PhD, Thomas Kaufman, Liqin Liu, PhD, Ralph F. Alderson, PhD, Kurt Stahl, Jennifer G. Brown, PhD, Hua Li, Sharad Sharma, PhD, James Tamura, PhD, Syd Johnson, PhD, Paul Moore, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5230.
https://doi.org/10.1182/blood-2018-99-116264
Published: 2018
Journal Articles

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Geoffrey L. Uy, MD, Michael P. Rettig, PhD, Norbert Vey, MD PhD, John Godwin, MD, Matthew C Foster, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Max S. Topp, Gerwin Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Kendra L. Sweet, MD, Farhad Ravandi, MD, Sarah E. Church, PhD, Jayakumar Vadakekolathu, PhD, Sergio Rutella, MD PhD FRCPath, Jichao Sun, PhD, Kang Yang, Jan Baughman, MPH, Teia Curtis, PhD, Erin Timmeny, Kerri Cali, Kathy Tran, John Muth, MS, Ross La Motte-Mohs, PhD, Camille Poirot, Pharm.D., Athanasios Pallis, MD, Alessandra Cesano, MD PhD, Ezio Bonvini, MD, Jon Wigginton, MD, Bob Lowenberg, MD, Jan K Davidson-Moncada, MD PhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 764.
https://doi.org/10.1182/blood-2018-99-117085
Published: 2018
Journal Articles

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Michael P Rettig, PhD, John Godwin, MD, Norbert Vey, Bernard Fox, PhD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Daner Li, MS, Daniel Primo, PhD, Joan Ballesteros, PhD, Jichao Sun, PhD, Helene Lelièvre, PhD PharmD, Jan Baughman, MPH, Ross La Motte-Mohs, PhD, John Muth, MS, Paul Moore, PhD, Ezio Bonvini, MD, Jon Wigginton, John F DiPersio, MD PhD, Jan Davidson-Moncada, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1365.
https://doi.org/10.1182/blood.V130.Suppl_1.1365.1365
Published: 2017
Journal Articles

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Geoffrey L. Uy, MD, John Godwin, MD, Michael P Rettig, PhD, Norbert Vey, Matthew Foster, Martha L. Arellano, MD, David A. Rizzieri, MD, Max S. Topp, MD, Gerwin Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Helene Lelièvre, PhD PharmD, Ross La Motte-Mohs, PhD, Daner Li, MS, Jichao Sun, PhD, Kenneth Jacobs, MD, Karen Spohn, BS, Nadia Lonsdale, BA, Kathy Tran, Jan Baughman, MPH, Michele Shannon, PhD, Bernard Fox, PhD, Ezio Bonvini, MD, Jon Wigginton, Jan Davidson-Moncada, MD, John F DiPersio, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 637.
https://doi.org/10.1182/blood.V130.Suppl_1.637.637
Published: 2017